ArticleScientific reports2026
Identification and experimental validation of aging-related biomarkers in intervertebral disc degeneration.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Intervertebral disc degeneration (IDD) is a prevalent disease with an increasing incidence, and aging is a key risk factor for its progression. Therefore, this study aimed to explore the role of aging-related genes in IDD through bioinformatics analysis. Differentially expressed aging-related genes were obtained from the CellAge, GSE150408 and GSE124272 datasets, followed by biomarker screening via machine learning. Finally, the identified biomarkers were validated using reverse transcription-quantitative polymerase chain reaction (RT-qPCR), Western Blot (WB), and immunohistochemistry (IHC) assays. A total of 33 aging-related differentially expressed genes (DEGs) were screened in IDD, and machine learning combined with ROC curve analysis identified PPM1D, PIK3C2A, and BTG3 as aging-related biomarkers for IDD; Gene Set Enrichment Analysis (GSEA) revealed that these three biomarkers were enriched in gene functions including cellular senescence, multicellular organismal aging, negative regulation of cellular senescence, and Ribosome. In addition, the multifactorial regulatory network showed that transcription factor E2F1 and hsa-miR-147 co-regulated both PPM1D and BTG3. In experiments validating biomarker expression levels, BTG3 and PIK3C2A exhibited consistent expression trends across IHC, RT-qPCR, WB assays and the two datasets. BTG3 and PIK3C2A may play more critical roles in the progression of IDD, thereby providing novel insights for the development of new therapeutic strategies for IDD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.